Table 1.
Demographics and clinical characteristics of plasma donors included in this study.
| Subjects | Age (y) | CGG repeats | Sex | FXTAS stage |
|---|---|---|---|---|
| C1 | 29 | 30 | M | 0 |
| C2 | 54 | 30 | M | 0 |
| C3 | 23 | 29, 30 | F | 0 |
| C4* | 50.5 | 21 | M | 0 |
| C5 | 24 | 30 | M | 0 |
| C6 | 41.2 | 43 | M | 0 |
| C7 | 28.8 | 20, 33 | F | 0 |
| C8 | 26 | 30 | M | 0 |
| C9 | 33.7 | 23, 30 | F | 0 |
| C10 | 54 | 25, 33 | F | 0 |
| C11 | 25 | 24, 33 | F | 0 |
| C12 | 45 | 22, 33 | F | 0 |
| C13 | 24 | 23, 35 | F | 0 |
| C14 | 26.3 | 30, 37 | F | 0 |
| C15 | 41.5 | 20 | M | 0 |
| C16 | 57.4 | 23, 30 | F | 0 |
| P1 | 46.3 | 61 | M | 0 |
| P2 | 9.7 | 31, 63 | F | 0 |
| P3* | 8.4 | 180 | M | 0 |
| P4* | 24 | 31, 93 | F | 0 |
| P5 | 19.7 | 177 | M | 0 |
| P6 | 55.6 | 104 | M | 0 |
| P7 | 49.3 | 31, 86 | F | 0 |
| P8* | 17.3 | 16, 67 | F | 0 |
| P9 | 45.3 | 69 | M | 0 |
| P10 | 49.9 | 20, 98 | F | 0 |
| P11 | 9.1 | 160 | M | 0 |
| P12 | 55.4 | 30, 69 | F | 0 |
| P13 | 53 | 16, 67 | F | 0 |
| P14 | 33.1 | 30, 137 | F | 0 |
| P15 | 43.2 | 30, 106 | F | 0 |
| P16 | 38.4 | 33, 60 | F | 0 |
| P17* | 8.4 | 180 | M | 0 |
| P18 | 24 | 30, 79 | F | 0 |
| P19 | 25 | 67 | M | 0 |
| P20* | 62.5 | 105 | M | 4 |
| P21 | 61.3 | 96 | M | 4 |
| P22 | 61.8 | 110–130 | M | 1 |
| P23 | 59.1 | 33, 107 | F | 3 |
C and P refer to controls and carriers of the premutation, respectively. The number following the letter identifies the subject from which the fibroblasts were obtained.
*Receiving SSRIs.